Beta-arrestin-mediated signaling in the heart

Circulation Journal

Volumn 72, Issue 11, 2008, Pages 1725-1729

  Patel, Priyesh A ^a   Tilley, Douglas G ^a   Rockman, Howard A ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Beta 1 adrenergic receptor; Beta arrestin; Extracellular regulated kinase (ERK); G protein coupled receptor

Indexed keywords

ANGIOTENSIN 1A RECEPTOR; ANGIOTENSIN II; BETA 1 ADRENERGIC RECEPTOR; BETA ARRESTIN; BETA ARRESTIN 1; BETA ARRESTIN 2; CARVEDILOL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; G PROTEIN COUPLED RECEPTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE;

CELL STRAIN HEK293; CHRONIC DISEASE; DESENSITIZATION; ENZYME ACTIVATION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANIMALS; ARRESTINS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEART FAILURE; HUMANS; MAP KINASE SIGNALING SYSTEM; MYOCARDIUM; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ADRENERGIC, BETA-1;

EID: 55449131858     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0734     Document Type: Review

References (41)

1. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science 2005; 308: 512-517.
2. Freedman NJ, Liggett SB, Drachmann DE, Pei G, Caron MG, Lefkowitz RJ. Phosphorylation and desensitization of the human beta 1-adrenergic receptor: Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase. J Biol Chem 1995; 270: 17953-17961.
3. Moore CA, Milano SK, Benovic JL. Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 2007; 69: 451-482.
4. Rajagopal K, Lefkowitz RJ, Rockman HA. When 7 transmembrane receptors are not G protein-coupled receptors. J Clin Invest 2005; 115: 2971-2974.
5. Nelson CD, Perry SJ, Regier DS, Prescott SM, Topham MK, Lefkowitz RJ. Targeting of diacylglycerol degradation to M1 muscarinic receptors by beta-arrestins. Science 2007; 315: 663-666.
6. Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, et al. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science 2002; 298: 834-836.
7. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007; 26: 3113-3121.
8. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 2003; 100: 10782-10787.
9. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, et al. Beta-arrestin-mediated beta(1)-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 2007; 117: 2445-2458.
10. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, et al. Beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem 2006; 281: 1261-1273.
11. Charest PG, Oligny-Longpre G, Bonin H, Azzi M, Bouvier M. The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling. Cell Signal 2007; 19: 32-41.
12. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, et al. Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 2006; 281: 10856-10864.
13. Ahn S, Shenoy SK, Wei H, Lefkowitz RJ. Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 2004; 279: 35518-35525.
14. Tohgo A, Choy EW, Gesty-Palmer D, Pierce KL, Laporte S, Oakley RH, et al. The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem 2003; 278: 6258-6267.
15. Jarpe MB, Widmann C, Knall C, Schlesinger TK, Gibson S, Yujiri T, et al. Anti-apoptotic versus pro-apoptotic signal transduction: Checkpoints and stop signs along the road to death. Oncogene 1998; 17(11 Reviews): 1475-1482.
16. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996; 87: 619-628.
17. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284.
18. Allan LA, Morrice N, Brady S, Magee G, Pathak S, Clarke PR. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 2003; 5: 647-654.
19. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003; 22: 6785-6793.
20. Graves LM, Guy HI, Kozlowski P, Huang M, Lazarowski E, Pope RM, et al. Regulation of carbamoyl phosphate synthetase by MAP kinase. Nature 2000; 403: 328-332.
21. Stefanovsky V, Langlois F, Gagnon-Kubler T, Rothblum LI, Moss T. Growth factor signaling regulates elongation of RNA polymerase I transcription in mammals via UBF phosphorylation and r-chromatin remodeling. Mol Cell 2006; 21: 629-639.
22. Stefanovsky VY, Langlois F, Bazzett-Jones D, Pelletier G, Moss T. ERK modulates DNA bending and enhancesome structure by phosphorylating HMG1-boxes 1 and 2 of the RNA polymerase I transcription factor UBF. Biochemistry 2006; 45: 3626-3634.
23. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 1997; 16: 1909-1920.
24. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999; 51: 651-690.
25. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 2002; 415: 206-212.
26. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993; 87: 454-463.
27. Xiang Y, Kobilka BK. Myocyte adrenoceptor signaling pathways. Science 2003; 300: 1530-1532.
28. Zhai P, Yamamoto M, Galeotti J, Liu J, Masurekar M, Thaisz J, et al. Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 2005; 115: 3045-3056.
29. Rajagopal K, Whalen EJ, Violin JD, Stiber JA, Rosenberg PB, Premont RT, et al. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA 2006; 103: 16284-16289.
30. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283: 1295-1302.
31. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). A randomised trial. Lancet 1999; 353: 9-13.
32. Packer M, Fowler MB, Roecker EB, Coats AJ, Catus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-2199.
33. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, et al. A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA 2007; 104: 16657-16662.
34. Kuo FT, Lu TL, Fu HW. Opposing effects of beta-arrestin1 and beta-arrestin2 on activation and degradation of Src induced by protease-activated receptor 1. Cell Signal 2006; 18: 1914-1923.
35. Kumar P, Lau CS, Mathur M, Wang P, DeFea KA. Differential effects of beta-arrestins on the internalization, desensitization and ERK1/2 activation downstream of protease activated receptor-2. Am J Physiol Cell Physiol 2007; 293: C346-C357.
36. Sneddon WB, Friedman PA. Beta-arrestin-dependent parathyroid hormone-stimulated extracellular signal-regulated kinase activation and parathyroid hormone type 1 receptor internalization. Endocrinology 2007; 148: 4073-4079.
37. Fan H, Luttrell LM, Tempel GE, Senn JJ, Halushka PV, Cook JA, et al. Beta-arrestins 1 and 2 differentially regulate LPS-induced signaling and pro-inflammatory gene expression. Mol Immunol 2007; 44: 3092-3099.
38. Xu TR, Baillie GS, Bhari N, Houslay TM, Pitt AM, Adams DR, et al. Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs: Implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKs. Biochem J 2008; 413: 51-60.
39. DeFea KA. Beta-arrestin multimers: Does a crowd help or hinder function? Biochem J 2008; 413: e1-e3.
40. Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, Shenoy SK, et al. Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci USA 2007; 104: 12011-12016.
41. Engelhardt S. Alternative signaling: Cardiomyocyte beta1-adrenergic receptors signal through EGFRs. J Clin Invest 2007; 117: 2396-2398.